A Phase II proof of concept study of liver-selective glucokinase (GK) activator TTP-399 as an oral drug for the treatment of Type 1 Diabetes.
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs TTP 399 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 08 Sep 2017 New trial record